Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Profile
Rex Eupseiphos's Profile
Displaying 101-150 of 156 result(s).
CYDY CytoDyn Inc
05/28/2020 10:09:02 AM
the sooner the better only if the n
CYDY CytoDyn Inc
05/27/2020 2:06:23 PM
"some say" + pretty much any crazy (1)
CYDY CytoDyn Inc
05/26/2020 3:24:53 PM
enrollment is the biggest issue for
CYDY CytoDyn Inc
05/26/2020 3:21:51 PM
Oh, that's awesome, FIREwithCYDY. G
CYDY CytoDyn Inc
05/26/2020 2:05:50 PM
I don't think that's right, but I'm
CYDY CytoDyn Inc
05/26/2020 1:19:33 PM
yep, enrollment is key. I thought t
CYDY CytoDyn Inc
05/26/2020 12:16:57 AM
I'm thinking it's 75-25 for reachin (2)
CYDY CytoDyn Inc
05/25/2020 10:50:23 PM
Worst case? August 1 for mild/mediu (2)
CYDY CytoDyn Inc
05/25/2020 4:49:46 PM
Why are we on the to invest or not (3)
CYDY CytoDyn Inc
05/25/2020 11:28:38 AM
itoliumab: "A few patients have bee (2)
CYDY CytoDyn Inc
05/24/2020 1:03:58 PM
He's wrong. Survival rates among EC (1)
CYDY CytoDyn Inc
05/24/2020 1:01:11 PM
The 24.5% "revision" is misleading. (1)
CYDY CytoDyn Inc
05/24/2020 12:24:52 PM
Not at all. The point is that we ar
CYDY CytoDyn Inc
05/24/2020 11:58:23 AM
An assumption of the two-sample tes (3)
CYDY CytoDyn Inc
05/24/2020 1:16:13 AM
Well, 11 patients are not a whole l (3)
CYDY CytoDyn Inc
05/23/2020 6:30:31 PM
My P.S. just means that TechGuru's
CYDY CytoDyn Inc
05/23/2020 6:28:08 PM
Zero chance of completed trial resu (5)
CYDY CytoDyn Inc
05/23/2020 6:12:46 PM
I agree that 5/10 survival from the (1)
CYDY CytoDyn Inc
05/23/2020 2:08:28 PM
our patients survive by far above s
CYDY CytoDyn Inc
05/23/2020 1:13:59 AM
I agree, but I listened to Dr Yo an
CYDY CytoDyn Inc
05/22/2020 9:55:26 PM
EUA would be interesting too (altho
CYDY CytoDyn Inc
05/22/2020 3:25:23 PM
what a horrific story of the inhere (3)
CYDY CytoDyn Inc
05/22/2020 1:24:16 PM
"Plutarhcy" and "oligarchy" are abs (2)
CYDY CytoDyn Inc
05/21/2020 2:34:53 PM
or he misspoke last week maybe? He
CYDY CytoDyn Inc
05/21/2020 9:32:10 AM
I don't think he misspoke because h
CYDY CytoDyn Inc
05/21/2020 2:06:41 AM
Interesting new paper on the possib (4)
CYDY CytoDyn Inc
05/20/2020 4:23:33 PM
Didn't GILD have two placebo arms b
CYDY CytoDyn Inc
05/20/2020 1:11:43 PM
stop loss can get you killed by sho (2)
CYDY CytoDyn Inc
05/19/2020 11:04:26 PM
tocilizumab has more serious side e (4)
CYDY CytoDyn Inc
05/19/2020 9:51:04 PM
amazing...this guy doesn't seem to (2)
CYDY CytoDyn Inc
05/19/2020 9:14:33 AM
Ha! You're of course right...and I (1)
CYDY CytoDyn Inc
05/19/2020 8:53:43 AM
Hopefully the dramatic "results" re (1)
CYDY CytoDyn Inc
05/18/2020 11:02:26 PM
That's funny! Dr P ain't going anyw
CYDY CytoDyn Inc
05/18/2020 7:47:50 PM
The short attacks seem to have pete
CYDY CytoDyn Inc
05/18/2020 3:09:36 PM
oh for crying out loud! you say you (1)
CYDY CytoDyn Inc
05/18/2020 2:37:19 PM
Do you suppose Dr. P gets samples a
CYDY CytoDyn Inc
05/18/2020 10:11:08 AM
Dr P is sort of an add-on to the tr (9)
CYDY CytoDyn Inc
05/17/2020 3:06:54 PM
Baricitinib? tocilizumab?
CYDY CytoDyn Inc
05/13/2020 1:55:33 PM
NP seems to bring EVERYTHING up. Wi
CYDY CytoDyn Inc
05/13/2020 1:45:42 PM
If it actually happened it would be
CYDY CytoDyn Inc
05/13/2020 9:52:34 AM
Two things removed a ton of doubts
CYDY CytoDyn Inc
05/13/2020 12:26:41 AM
assuming the results are good!
CYDY CytoDyn Inc
05/13/2020 12:10:28 AM
"How is it that the person in charg (7)
CYDY CytoDyn Inc
05/12/2020 8:07:36 PM
...looks like an outline for Wed we
CYDY CytoDyn Inc
05/11/2020 6:36:06 PM
The patients in Patterson's study w
CYDY CytoDyn Inc
05/11/2020 6:30:08 PM
Understood...a massive project. It
CYDY CytoDyn Inc
05/11/2020 6:25:04 PM
You are right. I was hoping for com
CYDY CytoDyn Inc
05/11/2020 6:18:05 PM
"benefit of the doubt"...yes, in th
CYDY CytoDyn Inc
05/11/2020 5:04:01 PM
I'm with you, Jim. The perpetual no
CYDY CytoDyn Inc
05/10/2020 7:48:46 PM
yes, annoying. (1)
Go to page:
  • << First
  • < Previous
  • 2
  • 3
  • Next >

Recent Articles

  • Evil Genius Games Partners with Living Dead Media for New Adventures
  • Cetera Financial Group's Innovative Wealth Management Solution
  • HydraVault Launches Advanced AI Facility Construction in Chicago
  • BLAZE Introduces Innovative AI Solutions for Cannabis Retail
  • Global Call to Action for Lennox-Gastaut Syndrome Awareness
  • AI Adoption in Automotive Deals: A Real-World Perspective
  • SharpLink Initiates $200M ETH Deployment Enhancing DeFi Yield
  • ProPhase Labs Strengthens Investor Engagement with RedChip
  • NANO Nuclear Energy Transforms to True North Nuclear for Growth
  • California BanCorp Achieves $15.7 Million Profit in Q3 2025
  • Medela Unveils Campaign to Celebrate Motherhood's Small Steps
  • VenHub Strengthens Position in Retail Automation by Joining NRF
  • Josh Ruben Joins the Board of PetVivo Holdings to Drive Growth
  • Newton Golf Expands E-Commerce with Japanese Market Site Launch
  • Innovative Gene Therapy SPVN20 Begins Patient Trials for Vision
  • Step Pharma Welcomes Dr. Karen Smith as New CMO to Innovate Cancer Care
  • Strategic Choices and Future Prospects for DEMIRE Real Estate
  • Independent Bank Corporation Announces Impressive Q3 Growth
  • VEON's JazzCash Secures Prestigious Silver Award in Lending
  • Context Therapeutics Announces Key Upcoming Investor Events
  • WeRide's CEO Lock-Up Enhances Shares Confidence During HKIPO
  • Nucor Corp Analysts Predict Strong Growth Amid Fluctuations
  • Recent Insights on Major Tech Stocks from CNBC's Trades
  • Strategic Sales Approach at DEMIRE to Boost Future Valuations
  • Cabinets To Go Launches Exciting New Showroom in Bowling Green
  • Odd Burger Terminates Placement Agreement Due to Default
  • FG Nexus Unveils Plans for Upcoming Conference in New York
  • D.R. Horton Faces Affordability Challenges as 2026 Approaches
  • Support for Andrew Cuomo to Lead Innovation in NYC
  • Pasadena Private Lending Secures $150 Million Credit Boost
  • Innovative Strategies and Future Directions from BioNTech's R&D Day
  • ATI Reports Impressive Q3 2025 Financial Performance and Outlook
  • Medidata and Sanofi Join Forces to Enhance Clinical Trials
  • Exploring the Latest Trends in Identity Theft and Its Impact
  • Innovative Immersive Learning Solutions for Healthcare Training
  • Addressing Emergency Response Costs: A Critical Analysis
  • Edesa Biotech's Phase 3 Study Shows Significant ARDS Treatment Success
  • Commvault Reports Impressive Q2 FY 2026 Financial Results
  • NXP's Strategic Acquisitions Enhance AI and Automotive Tech
  • Lupin Limited Unveils New Corporate Offices to Boost Operations
  • DEMIRE AG Delays Bond Repayment to Optimize Real Estate Sales
  • Polar Power Secures Military Contract for Innovative Generators
  • Blaqclouds Strengthens Leadership with Dr. Tony Ratliff's Appointment
  • How Lantronix's AI Technology Transforms Drone Operations
  • ZenaTech Showcases AI Drones at Major Defense Conferences
  • TG Therapeutics Completes ENHANCE Trial Enrollment for BRIUMVI
  • NextGen Partners with Resi Labs to Enhance Real Estate AI
  • Ayurcann Celebrates Record Sales and Dynamic Growth Strategy
  • Top Stock Upgrades You Should Know About Now
  • Repligen Achieves Significant Growth in Q3 2025 Financials
  • Home - Investors HangoutHome

  • Mailbox - Investors HangoutMailbox

  • Boards - Investors HangoutBoards

  • Favorites - Investors HangoutFavorites

  • Whats Hot! - Investors HangoutWhats Hot!

  • More - Investors HangoutMore

  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site